Search Results

Willow Biosciences Inc. today announced a collaboration with Enterin, Inc. to develop new sustainable manufacturing routes to their key intermediates and active pharmaceutical ingredients (APIs).

Enterin Inc., a privately held, Philadelphia-based, clinical-stage biopharmaceutical company pioneering novel treatments for neurodegenerative and metabolic diseases, today announced the start of a Phase 1a study in obesity and Type 2 diabetes (IND #155001).

Enterin Inc. announces the acceptance by the U.S. Food and Drug Administration (FDA) of an investigator sponsored Investigational New Drug (IND) application (166532) to treat a patient with prodromal multisystem atrophy (MSA) with ENT-01.

Enterin Inc., a privately held, Philadelphia-based, clinical-stage biopharmaceutical company developing novel treatments for neurodegenerative and metabolic diseases, announces that David Vogel has joined the Board of Directors.

Enterin Inc. announces a collaboration with the Parkinson’s Virtual Biotech, the drug development and discovery arm of Parkinson’s UK. A new phase 2 trial will study the effects of ENT-01 on Parkinson’s Disease -associated dementia.

Enterin Inc., a privately held, Philadelphia-based, clinical-stage biopharmaceutical company pioneering novel treatments for neurodegenerative and metabolic diseases, presented in vivo data demonstrating benefit on body weight, adiposity and blood glucose of ENT-03 compared to semaglutide in an obese, diabetic animal model, with persistence of benefit on weight beyond treatment.

Enterin Inc. announces the publication of its Phase 2a RASMET study.

Enterin Inc., a CNS pharmaceutical company based in Philadelphia and developing novel compounds to treat Parkinson’s disease, has enrolled the first patient in the DEMET study.